[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Water Pik, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":98},{"warningLetters":4,"total":97},[5,32,55,76],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},411,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-12-16T05:00:00Z\">12\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-13T05:00:00Z\">11\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flongford-water-company-llc-708114-11132025\">Longford Water Company LLC\u003C\u002Fa>","Office of Compliance and Enforcement","Processing &amp; Bottling of Bottled Drinking Water Regulations\u002FAdulterated\u003Cbr \u002F>\r\n","","Processing & Bottling of Bottled Drinking Water Regulations\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Dispatch\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Catherine M Girton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Longford Water Company LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>526 Santa Fe Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Longford\u003C\u002Fspan>, \u003Cspan>KS\u003C\u002Fspan> \u003Cspan>67458\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cgirton@longfordwater.com\"> cgirton@longfordwater.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Compliance and Enforcement\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS Case #708114\u003C\u002Fp>\u003Cp>\u003Cbr>Dear Ms. Catherine Girton:\u003C\u002Fp>\u003Cp>On March 17-18, 2025, the United States Food and Drug Administration (FDA) conducted an inspection of your bottled water facility, located at 526 Santa Fe Ave, Longford, KS 67458. During our inspection of your facility, the FDA investigators findings revealed serious violations of the Processing and Bottling of Bottled Drinking Water Regulations, Title 21, Code of Federal Regulations (21 CFR), Part 129. These violations render the bottle water products processed at your facility adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4), because the product has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. You may find the Act and FDA’s regulations through links on FDA’s Internet home page at www.fda.gov.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response to the Form FDA 483, Inspectional Observations, via email dated March 19, 2025, March 24, 2025, and March 27, 2025, received by our office. Details of FDA’s review of these responses are listed below.\u003C\u002Fp>\u003Cp>Your significant violations were as follows:\u003C\u002Fp>\u003Cp>1. You failed to ensure the treatment of product water by \u003Cstrong>(b)(4)\u003C\u002Fstrong> is done in a manner effective in accomplishing its intended purpose and in accordance with section 409 of the Act, as required by 21 CFR 129.80(a).\u003C\u002Fp>\u003Cp>Specifically, during start-up of production, you check the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter to make sure that it is not below \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm \u003Cstrong>(b)(4)\u003C\u002Fstrong> or above \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or that the pump is turned off. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> parameters used were futher described by your plant manager as \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm in an enclosed system for \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes. However, you could not provide any data or information showing this water treatment process using \u003Cstrong>(b)(4)\u003C\u002Fstrong> is effective in accomplishing its intended purpose of water sanitation. Furthermore, you do not maintain records of the performance (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentration and treatment duration) and effectiveness of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment, nor do you collect product water samples after processing and prior to bottling to demonstrate your \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment process results in a maximum residual level at the time of bottling that does not exceed 0.4 mg\u002FL, as required by 21 CFR 184.1563.\u003C\u002Fp>\u003Cp>In your written response, dated March 24, 2025, you provided a certificate of analysis for total coliforms and \u003Cem>E. coli\u003C\u002Fem> testing on one sample water collected prior to filling; however, you did not provide any records of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentration and treatment duration, details about how you plan to collect and analyze this type of sample, or training records associated with any updated program. You also did not provide any information on the effectiveness of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment process for its intended purpose of water sanitation.\u003C\u002Fp>\u003Cp>2. You failed to conduct and analyze at least once a week for bacteriological purposes a representative sample from a batch or segment of a continuous production run for each type of bottled drinking water produced during a day's production, as required by 21 CFR 129.80(g)(1).\u003C\u002Fp>\u003Cp>Specifically \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you produce different types of drinking water, including Purified Drinking Water and Drinking Water; you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> different production lines; and you do not sample each type of bottled water at least once a week.\u003Cbr>Furthermore, you do not dechlorinate the sample collected prior to testing as indicated in the directions for use for the test.\u003C\u002Fp>\u003Cp>In your written response, dated March 24, 2025, you provided an updated log which provides a space to fill in for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step and for collected bottle sizes. However, you have not demonstrated that you are testing each type of bottled water and did not provide a procedure explaining the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step or the implementation of this process.\u003C\u002Fp>\u003Cp>3. You failed to sample and inspect containers and closures, which includes making a bacteriological swab and\u002For rinse count at least once each quarter from at least four containers and closures selected just prior to filling and sealing, to ensure they are free from contamination, as required by 21 CFR 129.80(f).\u003C\u002Fp>\u003Cp>Specifically, you stated you do not conduct any testing of your containers or closures.\u003C\u002Fp>\u003Cp>In your written response, dated March 27, 2025, you stated you are still researching appropriate corrective actions.\u003C\u002Fp>\u003Cp>4. You do not clean and adequately sanitize product water-contact surfaces of all multiservice containers, utensils, pipes, and equipment used in the transportation, processing, handling, and storage of product water, as required by 21 CFR 129.37(a). Specifically, you do not clean all your product water contact utensils or equipment. You conduct sanitizing with \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm chlorine \u003Cstrong>(b)(4)\u003C\u002Fstrong> a month. Furthermore, you do not keep complete records for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations.\u003C\u002Fp>\u003Cp>In your written responses, dated March 19, 2025 and March 24, 2025, you provided an updated monthly \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The updated log contains limited information for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and indicates that you are now using “\u003Cstrong>(b)(4)\u003C\u002Fstrong> soap for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and indicates you used \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm \u003Cstrong>(b)(4)\u003C\u002Fstrong>” for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The log lists some product water contact surfaces for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, and other surfaces of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” equipment and the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. However, the updated form does not include all product water contact surfaces, such as the product water lines, nor does it include duration of treatment. Furthermore, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> log for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> does not include the duration of treatment. Also, you did not provide associated updated SOPs for \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your response.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps and corrections you have taken and to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\u003Cp>Your written response should be sent electronically to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Andrew Hoopes, Compliance Officer, at Andrew.Hoopes@fda.hhs.gov. Please include reference CMS Case #708114 on any submissions and within the subject line of any email correspondence to the agency. If you have questions regarding this letter, please contact Andrew Hoopes, Compliance Officer, at Andrew.Hoopes@fda.hhs.gov.\u003Cbr>\u003Cbr>Sincerely,\u003C\u002Fp>\u003Cp>\u002Fs\u002F\u003Cbr>Maria S. Knirk, JD MBA Acting Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Dispatch\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nCatherine M Girton\n\nRecipient Title\n\nOwner\n\nLongford Water Company LLC\n\n526 Santa Fe Ave\n\nLongford, KS 67458\n\nUnited States\n\ncgirton@longfordwater.com\n\nIssuing Office:\n\nOffice of Compliance and Enforcement\n\nUnited States\n\nNovember 13, 2025\nWARNING LETTER\nRe: CMS Case #708114\n\nDear Ms. Catherine Girton:\nOn March 17-18, 2025, the United States Food and Drug Administration (FDA) conducted an inspection of your bottled water facility, located at 526 Santa Fe Ave, Longford, KS 67458. During our inspection of your facility, the FDA investigators findings revealed serious violations of the Processing and Bottling of Bottled Drinking Water Regulations, Title 21, Code of Federal Regulations (21 CFR), Part 129. These violations render the bottle water products processed at your facility adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4), because the product has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. You may find the Act and FDA’s regulations through links on FDA’s Internet home page at www.fda.gov.\nWe acknowledge receipt of your response to the Form FDA 483, Inspectional Observations, via email dated March 19, 2025, March 24, 2025, and March 27, 2025, received by our office. Details of FDA’s review of these responses are listed below.\nYour significant violations were as follows:\n1. You failed to ensure the treatment of product water by (b)(4) is done in a manner effective in accomplishing its intended purpose and in accordance with section 409 of the Act, as required by 21 CFR 129.80(a).\nSpecifically, during start-up of production, you check the (b)(4) meter to make sure that it is not below (b)(4)ppm (b)(4) or above (b)(4)ppm (b)(4), or that the pump is turned off. The (b)(4) parameters used were futher described by your plant manager as (b)(4)ppm in an enclosed system for (b)(4) minutes. However, you could not provide any data or information showing this water treatment process using (b)(4) is effective in accomplishing its intended purpose of water sanitation. Furthermore, you do not maintain records of the performance (e.g., (b)(4) concentration and treatment duration) and effectiveness of your (b)(4) treatment, nor do you collect product water samples after processing and prior to bottling to demonstrate your (b)(4) treatment process results in a maximum residual level at the time of bottling that does not exceed 0.4 mg\u002FL, as required by 21 CFR 184.1563.\nIn your written response, dated March 24, 2025, you provided a certificate of analysis for total coliforms and E. coli testing on one sample water collected prior to filling; however, you did not provide any records of the (b)(4) concentration and treatment duration, details about how you plan to collect and analyze this type of sample, or training records associated with any updated program. You also did not provide any information on the effectiveness of your (b)(4) treatment process for its intended purpose of water sanitation.\n2. You failed to conduct and analyze at least once a week for bacteriological purposes a representative sample from a batch or segment of a continuous production run for each type of bottled drinking water produced during a day's production, as required by 21 CFR 129.80(g)(1).\nSpecifically (b)(4). However, you produce different types of drinking water, including Purified Drinking Water and Drinking Water; you use (b)(4) different production lines; and you do not sample each type of bottled water at least once a week.\nFurthermore, you do not dechlorinate the sample collected prior to testing as indicated in the directions for use for the test.\nIn your written response, dated March 24, 2025, you provided an updated log which provides a space to fill in for the (b)(4) step and for collected bottle sizes. However, you have not demonstrated that you are testing each type of bottled water and did not provide a procedure explaining the (b)(4) step or the implementation of this process.\n3. You failed to sample and inspect containers and closures, which includes making a bacteriological swab and\u002For rinse count at least once each quarter from at least four containers and closures selected just prior to filling and sealing, to ensure they are free from contamination, as required by 21 CFR 129.80(f).\nSpecifically, you stated you do not conduct any testing of your containers or closures.\nIn your written response, dated March 27, 2025, you stated you are still researching appropriate corrective actions.\n4. You do not clean and adequately sanitize product water-contact surfaces of all multiservice containers, utensils, pipes, and equipment used in the transportation, processing, handling, and storage of product water, as required by 21 CFR 129.37(a). Specifically, you do not clean all your product water contact utensils or equipment. You conduct sanitizing with (b)(4)ppm chlorine (b)(4) a month. Furthermore, you do not keep complete records for your (b)(4) operations.\nIn your written responses, dated March 19, 2025 and March 24, 2025, you provided an updated monthly (b)(4). The updated log contains limited information for (b)(4) and indicates that you are now using “(b)(4) soap for (b)(4), and indicates you used (b)(4) ppm (b)(4)” for (b)(4). The log lists some product water contact surfaces for the “(b)(4)”, and other surfaces of the “(b)(4)” equipment and the “(b)(4)”. However, the updated form does not include all product water contact surfaces, such as the product water lines, nor does it include duration of treatment. Furthermore, your (b)(4) log for the (b)(4) does not include the duration of treatment. Also, you did not provide associated updated SOPs for (b)(4) in your response.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps and corrections you have taken and to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\nYour written response should be sent electronically to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Andrew Hoopes, Compliance Officer, at Andrew.Hoopes@fda.hhs.gov. Please include reference CMS Case #708114 on any submissions and within the subject line of any email correspondence to the agency. If you have questions regarding this letter, please contact Andrew Hoopes, Compliance Officer, at Andrew.Hoopes@fda.hhs.gov.\n\nSincerely,\n\u002Fs\u002F\nMaria S. Knirk, JD MBA Acting Director\nOffice of Enforcement\nOffice of Compliance and Enforcement Human Foods Program","Longford Water Company LLC","longford-water-company-llc-708114-11132025","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flongford-water-company-llc-708114-11132025","2026-10-26T08:09:16.148526+00:00","Warning Letter","Issued","2025-12-16","708114","Food & Beverages","Catherine M Girton","2026-08-19T16:09:07.425+00:00","VIA Dispatch","2025-11-13",{"id":33,"raw":34,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":24,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":20,"issuing_office":38,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":20,"reference_number":20,"action_taken_date":54,"medical_device_id":20,"response_letter_date":20},3141,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2021-09-14T13:20:00Z\">09\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-07T04:00:00Z\">09\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcdaniel-water-llc-616186-09072021\">McDaniel Water, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded ","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gary McDaniel\u002FRuth Shields\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Directors\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>McDaniel Water, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>23711 Hix Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canyon\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>79015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mcdanielwater@gmail.com\"> mcdanielwater@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 7, 2021\u003C\u002Fp>\n\n\u003Cp>Ruth Shields, Director\u003Cbr>\nMcDaniel Water LLC\u003Cbr>\n363 Ricketson Road\u003Cbr>\nAmistad, NM 88410\u003C\u002Fp>\n\n\u003Cp>RE: 616186\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McDaniel and Ms. Shields:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that in July 2021 the U.S. Food and Drug Administration (FDA) reviewed your product labeling and your website at the Internet address www.mcdanielwater.com and has observed that you take orders there for the product “Black Indian Salve,” which you also refer to on your website as “Indian Herb,” “X,” and “Black Salve.” As explained further below, this product is an unapproved new drug sold in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 301(d). You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Your “Black Indian Salve” is concerning from a public health perspective because it is labeled to contain the ingredients bloodroot (Sanguinaria canadensis) and zinc chloride. Both substances are known corrosive agents. The combination of bloodroot and zinc chloride results in a corrosive topical agent capable of indiscriminately damaging healthy and diseased tissue alike and forming eschar (sloughed dead tissue). The tissue necrosis caused by topical application of products containing such ingredients (often referred to as \"black salves\") is well-documented.\u003C\u002Fp>\n\n\u003Cp>On May 16, 2019, the FDA issued a warning letter to McDaniel Life-Line LLC which offered a similar product, “Indian Herb,” for sale directly to consumers. The agency advises you that on February 8, 2019, “Indian Herb” was the subject of a voluntary worldwide recall of all lots of the product that were within expiration. In addition, the FDA Center for Drug Evaluation and Research (CDER) issued a safety alert on February 12, 2019 concerning the potential safety hazard associated with “Indian Herb” (see Indian Herb FDA Alert).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You market “Black Indian Salve” as a dietary supplement with directions for both topical application and for ingestion. However, “Black Indian Salve” does not meet the definition of a dietary supplement under section 201(ff) of the FD&amp;C Act. Only products that are intended solely for ingestion may be lawfully marketed as dietary supplements. See section 201(ff)(2)(A)(i) of the FD&amp;C Act, 21 U.S.C. 321(ff)(2)(A)(i). Topical products and products intended to enter the body through the skin or mucosal tissues are not dietary supplements. Therefore, your “Black Indian Salve” is not a dietary supplement.\u003C\u002Fp>\n\n\u003Cp>Rather, claims on your product labeling and your website establish that “Black Indian Salve” is a drug as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For to affect the structure or function of the body. Examples of claims on your product label and website that establish the intended use of your “Black Indian Salve” product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Black Indian Salve\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>From the package insert accompanying the product:\u003C\u002Fp>\n\n\u003Cp>• “The following guidelines are offered for the application of ‘The Black Indian Salve’ in treating various types of abnormal growths both external and internal. . . . This is how people have used the ‘Black Indian Salve’ on external growths . . . The ‘Black Indian Salve’ is tracing out the infected area and drawing the poison back into the nucleus. It will make a hard core, similar to the core of a boil – hard and rubbery. The redness will diminish and a white ring will begin to appear around the nucleus. . . . Between the fifth and seventh day, a white ring will start to separate from the healthy tissue and become very loose. . . . Usually after the second application the growth itself is dead. The growth will become more painful as the body begins to eject its dying tissue. Swelling often occurs. . . . The core will not come out unless the whole growth is dead and detached from the healthy tissue. Then and only then will it come out intact. There will be no need for surgery. . . . For most people, in about 10 days the body completely pushes out the dead growth and the fever disappears. . . During the next 10 days, or as long as it takes, the body will fill in the cavity with either healthy tissue or scar tissue, depending on the individual’s body chemistry and health. . . . In many cases of removing external growths, people report that even though large masses of tissue was ejected from the body, even to the point of revealing the muscle structure below, bleeding did not occur and the body completely filled in the area where the growth had been.”\u003C\u002Fp>\n\n\u003Cp>From the website http:\u002F\u002Fmcdanielwater.com\u002Fpage12.html:\u003C\u002Fp>\n\n\u003Cp>• “The Indian Herb is a 100-year-old folk remedy used to attack disease and aid in the healing process. It is also often referred to as ‘X’ or ‘Black Salve’. Indian Herb may be taken internally or applied externally to abnormal skin growths.”\u003Cbr>\n• “\u003Cstrong>Yellow Dock\u003C\u002Fstrong> contains iron and can improve the function of the liver, kidneys, lymph glands and intestines. It has been used for the treatment of jaundice . . ..”\u003Cbr>\n• “\u003Cstrong>Blood Root\u003C\u002Fstrong> is considered highly effective for skin conditions . . . Its primary alkaloid, sanguinarine, has been found to be a potent anti-cancer agent. It is prized for its ability to heal infections &amp; stimulate healthy tissue growth.”\u003Cbr>\n• “\u003Cstrong>Licorice Root\u003C\u002Fstrong> has been known to enhance immunity by boosting the level of interferon.”\u003Cbr>\n• “\u003Cstrong>Galangal\u003C\u002Fstrong> . . . In recent studies, it was also found to have anti-cancer activities. It acts as an anti-oxidant and suppresses the genotoxicity of chemicals. Genotoxic substances are known to be potentially mutagenic or potentially cancerous.”\u003C\u002Fp>\n\n\u003Cp>Your “Black Indian Salve” product is also a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in its labeling. Under section 505(a) of the FD&amp;C Act, a new drug may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA. There is no FDA-approved application in effect for your “Black Indian Salve.” Thus, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance, 10903 New Hampshire Avenue, WO51, Silver Spring, MD 20993-0002 by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCarolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nGary McDaniel\u002FRuth Shields\n\nRecipient Title\n\nDirectors\n\nMcDaniel Water, LLC\n\n23711 Hix Drive\n\nCanyon, TX 79015\n\nUnited States\n\nmcdanielwater@gmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSeptember 7, 2021\n\nRuth Shields, Director\n\nMcDaniel Water LLC\n\n363 Ricketson Road\n\nAmistad, NM 88410\n\nRE: 616186\n\nDear Mr. McDaniel and Ms. Shields:\n\nThis letter is to advise you that in July 2021 the U.S. Food and Drug Administration (FDA) reviewed your product labeling and your website at the Internet address www.mcdanielwater.com and has observed that you take orders there for the product “Black Indian Salve,” which you also refer to on your website as “Indian Herb,” “X,” and “Black Salve.” As explained further below, this product is an unapproved new drug sold in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 301(d). You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nYour “Black Indian Salve” is concerning from a public health perspective because it is labeled to contain the ingredients bloodroot (Sanguinaria canadensis) and zinc chloride. Both substances are known corrosive agents. The combination of bloodroot and zinc chloride results in a corrosive topical agent capable of indiscriminately damaging healthy and diseased tissue alike and forming eschar (sloughed dead tissue). The tissue necrosis caused by topical application of products containing such ingredients (often referred to as \"black salves\") is well-documented.\n\nOn May 16, 2019, the FDA issued a warning letter to McDaniel Life-Line LLC which offered a similar product, “Indian Herb,” for sale directly to consumers. The agency advises you that on February 8, 2019, “Indian Herb” was the subject of a voluntary worldwide recall of all lots of the product that were within expiration. In addition, the FDA Center for Drug Evaluation and Research (CDER) issued a safety alert on February 12, 2019 concerning the potential safety hazard associated with “Indian Herb” (see Indian Herb FDA Alert).\n\nUnapproved New Drug Violations\n\nYou market “Black Indian Salve” as a dietary supplement with directions for both topical application and for ingestion. However, “Black Indian Salve” does not meet the definition of a dietary supplement under section 201(ff) of the FD&C Act. Only products that are intended solely for ingestion may be lawfully marketed as dietary supplements. See section 201(ff)(2)(A)(i) of the FD&C Act, 21 U.S.C. 321(ff)(2)(A)(i). Topical products and products intended to enter the body through the skin or mucosal tissues are not dietary supplements. Therefore, your “Black Indian Salve” is not a dietary supplement.\n\nRather, claims on your product labeling and your website establish that “Black Indian Salve” is a drug as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For to affect the structure or function of the body. Examples of claims on your product label and website that establish the intended use of your “Black Indian Salve” product as a drug include, but may not be limited to, the following:\n\nBlack Indian Salve\n\nFrom the package insert accompanying the product:\n\n• “The following guidelines are offered for the application of ‘The Black Indian Salve’ in treating various types of abnormal growths both external and internal. . . . This is how people have used the ‘Black Indian Salve’ on external growths . . . The ‘Black Indian Salve’ is tracing out the infected area and drawing the poison back into the nucleus. It will make a hard core, similar to the core of a boil – hard and rubbery. The redness will diminish and a white ring will begin to appear around the nucleus. . . . Between the fifth and seventh day, a white ring will start to separate from the healthy tissue and become very loose. . . . Usually after the second application the growth itself is dead. The growth will become more painful as the body begins to eject its dying tissue. Swelling often occurs. . . . The core will not come out unless the whole growth is dead and detached from the healthy tissue. Then and only then will it come out intact. There will be no need for surgery. . . . For most people, in about 10 days the body completely pushes out the dead growth and the fever disappears. . . During the next 10 days, or as long as it takes, the body will fill in the cavity with either healthy tissue or scar tissue, depending on the individual’s body chemistry and health. . . . In many cases of removing external growths, people report that even though large masses of tissue was ejected from the body, even to the point of revealing the muscle structure below, bleeding did not occur and the body completely filled in the area where the growth had been.”\n\nFrom the website http:\u002F\u002Fmcdanielwater.com\u002Fpage12.html:\n\n• “The Indian Herb is a 100-year-old folk remedy used to attack disease and aid in the healing process. It is also often referred to as ‘X’ or ‘Black Salve’. Indian Herb may be taken internally or applied externally to abnormal skin growths.”\n\n• “Yellow Dock contains iron and can improve the function of the liver, kidneys, lymph glands and intestines. It has been used for the treatment of jaundice . . ..”\n\n• “Blood Root is considered highly effective for skin conditions . . . Its primary alkaloid, sanguinarine, has been found to be a potent anti-cancer agent. It is prized for its ability to heal infections & stimulate healthy tissue growth.”\n\n• “Licorice Root has been known to enhance immunity by boosting the level of interferon.”\n\n• “Galangal . . . In recent studies, it was also found to have anti-cancer activities. It acts as an anti-oxidant and suppresses the genotoxicity of chemicals. Genotoxic substances are known to be potentially mutagenic or potentially cancerous.”\n\nYour “Black Indian Salve” product is also a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in its labeling. Under section 505(a) of the FD&C Act, a new drug may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA. There is no FDA-approved application in effect for your “Black Indian Salve.” Thus, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance, 10903 New Hampshire Avenue, WO51, Silver Spring, MD 20993-0002 by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","McDaniel Water, LLC","mcdaniel-water-llc-616186-09072021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcdaniel-water-llc-616186-09072021","2026-10-26T08:09:22.205882+00:00","2021-09-14","616186","Drugs","Gary McDaniel\u002FRuth Shields","2026-08-20T02:36:08.132+00:00","Via Email","2021-09-07",{"id":56,"raw":57,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":19,"fei_number":20,"letter_url":67,"updated_at":68,"action_type":23,"case_status":24,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":20,"issuing_office":61,"recipient_name":20,"body_fetched_at":72,"delivery_method":73,"recipient_title":20,"reference_number":74,"action_taken_date":75,"medical_device_id":20,"response_letter_date":20},156,[58,59,60,61,62,13,13,13],"\u003Ctime datetime=\"2026-05-19T04:00:00Z\">05\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-08T04:00:00Z\">05\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwaterbedsnstuffcom-729435-05082026\">waterbedsnstuff.com\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2602408\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>waterbedsnstuff.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3933 Brookham Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grove City\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>43123\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@waterbedsnstuff.com\"> sales@waterbedsnstuff.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@stuff4uwholesale.com\"> sales@stuff4uwholesale.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:admin@waterbedsnstuff.com\"> admin@waterbedsnstuff.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the https:\u002F\u002Fwaterbedsnstuff.com and determined that nicotine pouch products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1 (A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States nicotine pouch products that lack a marketing authorization order, including: Tyson 2.0 Nic Pouches – Citrus Hook and Tyson 2.0 Nic Pouches – Mint Brawler.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as ecommerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, RW2602408, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>FDA Center for Tobacco Products\u003Cbr>c\u002Fo Document Control Center\u003Cbr>Building 71, Room G335\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ele Ibarra-Pratt\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>cc:\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff, Inc.\u003Cbr>Attn: Gerald Spero\u003Cbr>6641 Meadow Lane\u003Cbr>Galena, OH 43021\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>815 S. Hamilton Rd\u003Cbr>Columbus, OH 43213\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>3592 Soldano Blvd\u003Cbr>Columbus, OH 43228\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>2194 N High St\u003Cbr>Columbus, OH 43201\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>1245 N Hamilton Rd\u003Cbr>Gahanna, OH 43230\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>1251 N Memorial Dr\u003Cbr>Lancaster, OH 43130\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>688 Hebron Rd\u003Cbr>Heath, OH 43056\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>885 N Bridge St\u003Cbr>Chillicothe, OH 45601\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>2230 Morse Rd\u003Cbr>Columbus, OH 43229\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>5846 Emporium Sq\u003Cbr>Columbus, OH 43231\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>6477 Sawmill Rd\u003Cbr>Dublin, OH 43017\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>720 Polaris Pkwy\u003Cbr>Lewis Center, OH 43035\u003C\u002Fp>\u003Cp>Waterbeds 'n' Stuff\u003Cbr>2177 State Route 256\u003Cbr>Reynoldsburg, OH 43068\u003C\u002Fp>\u003Cp>Bigcommerce Inc.\u003Cbr>abuse@bigcommerce.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2602408\n\nProduct:\n\nTobacco\n\nRecipient:\n\nwaterbedsnstuff.com\n\n3933 Brookham Drive\n\nGrove City, OH 43123\n\nUnited States\n\nsales@waterbedsnstuff.com\n\nsales@stuff4uwholesale.com\n\nadmin@waterbedsnstuff.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 8, 2026\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the https:\u002F\u002Fwaterbedsnstuff.com and determined that nicotine pouch products listed there are offered for sale or distribution to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1 (A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States nicotine pouch products that lack a marketing authorization order, including: Tyson 2.0 Nic Pouches – Citrus Hook and Tyson 2.0 Nic Pouches – Mint Brawler.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as ecommerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, RW2602408, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nEle Ibarra-Pratt\nActing Director\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\nVIA UPS and Electronic Mail\ncc:\nWaterbeds 'n' Stuff, Inc.\nAttn: Gerald Spero\n6641 Meadow Lane\nGalena, OH 43021\nWaterbeds 'n' Stuff\n815 S. Hamilton Rd\nColumbus, OH 43213\nWaterbeds 'n' Stuff\n3592 Soldano Blvd\nColumbus, OH 43228\nWaterbeds 'n' Stuff\n2194 N High St\nColumbus, OH 43201\nWaterbeds 'n' Stuff\n1245 N Hamilton Rd\nGahanna, OH 43230\nWaterbeds 'n' Stuff\n1251 N Memorial Dr\nLancaster, OH 43130\nWaterbeds 'n' Stuff\n688 Hebron Rd\nHeath, OH 43056\nWaterbeds 'n' Stuff\n885 N Bridge St\nChillicothe, OH 45601\nWaterbeds 'n' Stuff\n2230 Morse Rd\nColumbus, OH 43229\nWaterbeds 'n' Stuff\n5846 Emporium Sq\nColumbus, OH 43231\nWaterbeds 'n' Stuff\n6477 Sawmill Rd\nDublin, OH 43017\nWaterbeds 'n' Stuff\n720 Polaris Pkwy\nLewis Center, OH 43035\nWaterbeds 'n' Stuff\n2177 State Route 256\nReynoldsburg, OH 43068\nBigcommerce Inc.\nabuse@bigcommerce.com","waterbedsnstuff.com","waterbedsnstuffcom-729435-05082026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwaterbedsnstuffcom-729435-05082026","2026-10-26T08:10:30.623481+00:00","2026-05-19","729435","Tobacco","2026-08-19T04:42:03.532+00:00","VIA UPS and Electronic Mail","RW2602408","2026-05-08",{"id":77,"raw":78,"subject":40,"body_html":83,"body_text":84,"firm_name":85,"letter_id":86,"created_at":87,"fei_number":20,"letter_url":88,"updated_at":89,"action_type":23,"case_status":24,"posted_date":90,"marcs_cms_no":91,"product_type":92,"closeout_date":20,"issuing_office":93,"recipient_name":94,"body_fetched_at":95,"delivery_method":53,"recipient_title":20,"reference_number":20,"action_taken_date":96,"medical_device_id":20,"response_letter_date":20},2118,[79,80,81,82,40,13,13,13],"\u003Ctime datetime=\"2023-04-25T13:20:00Z\">04\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-08T05:00:00Z\">03\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspartan-enterprises-inc-dba-watershed-wellness-center-642030-03082023\">Spartan Enterprises Inc. dba Watershed Wellness Center\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert F. McCauley\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Spartan Enterprises Inc. dba Watershed Wellness Center\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16280 National Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lansing\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48906\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nFY23-HAFE6-01 CMS 642030\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 8, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. McCauley:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your dietary supplement manufacturing facility, located at 16280 National Parkway, Lansing MI, from June 29 through July 25, 2022. We also reviewed your websites at www.watershed.net and www.shop.watershed.net in December 2022, and your YouTube channel. Based on inspectional findings and a review of your websites, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at&nbsp;http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New\u002FMisbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the FDA reviewed your product labels following the inspection of your facility. In addition, FDA reviewed your website www.shop.watershed.net in December 2022, and determined you take orders there for the products Dr. Bob’s Naturals Spirulina, Dr. Bob’s Naturals Magtein, Dr. Bob’s Naturals Tulsi-Holy Basil Extract Capsules, Dr. Bob’s Naturals Milk Thistle Liver Support, Dr. Bob’s Naturals Stone Breaker Powder, Dr. Bob’s Parasite Killer, Dr. Bob’s Naturals Parasite Killer Bundle, Dr. Bob’s Naturals Parasite Killer Bundle MINI, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals Gingko Magic, and Dr. Bob’s Naturals Chlorella, and Raw Food World Ashwagandha Extract. We also reviewed your website www.watershed.net, which directs consumers to your website www.shop.watershed.net to purchase your products, and your YouTube Channel at www.youtube.com\u002Fc\u002FDrBobMcCauley, in December 2022. The claims on your product labels, websites, and your YouTube Channel establish that these products are drugs under section 201(g)(1)(B) of the Act [21 U.SC. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>From your website at www.watershed.net:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Spirulina [an ingredient in Dr. Bob’s Naturals Spirulina tablets]:\u003C\u002Fstrong> the following statements are included in the description: “Lowers LDL and Triglyceride Levels”, “Anti-Inflammatory Properties”, “Fights Anemia”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Ashwagandha [an ingredient in the Raw Food World Ashwagandha Extract]:\u003C\u002Fstrong> the following statements are included in the description: “It is commonly used to relieve…pain, skin, joint, digestive issues asn [sic] well as neurological issues.”\u003C\u002Fp>\n\n\u003Cp>From your website at www.shop.watershed.net:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Magtei:\u003C\u002Fstrong> “Magnesium repairs the damaged synapses of the brain, which is the cause of the various types of neurological and brain-related diseases.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Tulsi-Holy Basil Extract Capsules:\u003C\u002Fstrong>\u003Cbr>\n&nbsp; &nbsp; o “Regulates Insulin Levels to Help Balance Blood Sugar”\u003Cbr>\n&nbsp; &nbsp; o “Contains Antibacterial, Antifungal Properties”\u003Cbr>\n&nbsp; &nbsp; o “Holy Basil…regulates insulin levels…. It has Antibacterial, anti-fungal, and anti-inflammatory properties.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Milk Thistle Liver Support:\u003C\u002Fstrong>\u003Cbr>\n&nbsp; &nbsp; o “Milk Thistle ….is…anti-inflammatory”\u003Cbr>\n&nbsp; &nbsp; o “Benefits:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 Reduces Cholesterol\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 Anti-allergic\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 Asthma Support\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 Reduces Insulin Resistance\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 Anti-inflammatory”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Stone Breaker Powder:\u003C\u002Fstrong> “Stone Breaker (Chanca Piedra) has been used by the indigenous peoples of the Amazon Forests for centuries to treat and remove of [sic] kidney and gall stones. It helps dissolve the stones so they can be eliminated from the body. Chanca Piedra interferes with stone formation by relaxing urinary passages so small stones are more easily passed. It can be used in conjunction with lithotripsy, a shock wave procedure that fragments stones”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Parasite Killer Bundle:\u003C\u002Fstrong> “Six Products that kill viruses, bacteria, yeast, mold, and fungus in the bloodstream and digestive tract. Silver: Kills viruses, bacteria, yeast, mold, and fungus in the bloodstream. (16 oz) Bismuth: Kills bacteria in the digestive tract. (16 oz) Papaya Seed Powder: Parasite removal. Parasite Killer BlendTM: Kills viruses, bacteria, yeast, mold, and fungus in the digestive tract. Dissolve Bioactive Silicate: Removes biofilm and nano-bacteria from the arteries and body. Proferment [sic].”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Parasite Killer Bundle MINI: \u003C\u002Fstrong>“Dr. Bob’s Parasite Killer Bundle MINI is identical to Dr. Bob’s Parasite Killer Bundle except the bottles are 2 oz (NOT 16 oz). Six Products that kill viruses, bacteria, yeast, mold, and fungus in the bloodstream and digestive tract. Silver: Kills viruses, bacteria, yeast, mold, and fungus in the bloodstream. (2 oz) Bismuth: Kills bacteria in the digestive tract. (2 oz) Papaya Seed Powder: Parasite removal. Parasite Killer Blend\u003Csup>TM\u003C\u002Fsup>: Kills viruses, bacteria, yeast, mold, and fungus in the digestive tract. Dissolve Bioactive Silicate: Removes biofilm and nano-bacteria from the arteries and body. Preferment – Probiotic.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Parasite Killer:\u003C\u002Fstrong> “Dr. Bob’s Parasite Killer is formulated with parasiticidal, anti-fungal, anti-viral, and antibacterial ingredients with the intention of killing everything in the digestive tract. Once that is accomplished then the next step is to reintroduce probiotics, the friendly bacteria that…. keep our digestive tract free of parasites and unhealthy bacteria.”\u003C\u002Fp>\n\n\u003Cp>From your YouTube Channel:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>A video titled “Amazing herb – Little Known: YEW Tree with Taxane” [an ingredient in Dr. Bob’s Naturals Yew VeggieCaps]\u003C\u002Fstrong> at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=kudldIcMIXU, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “Very powerful anti-cancer properties…used in conjunction with chemotherapy and other cancer treatments, but not only does it have anti-cancer properties it also has a lot of other properties as well…the way that Taxane works in the body to fight cancer is it causes cell apoptosis in cancer cells. So it doesn’t allow the cancer cell to replicate…. Is also very powerful anti-inflammatory…on top of being anti-cancer…. you take two or three capsules a day as a maintenance dosage, or if you have a serious health challenge maybe you got cancer or something, you’re going to triple that dosage and do three of those three times a day ….”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your description of the video says, “Buy Yew Capsules Here” and hyperlinks to the Dr. Bob’s Naturals Yew VeggieCaps product page of your website, https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fherbal-extracts\u002Fimmune-system-builder\u002Fyew\u002Fyewcaps.html, and also contains the following written statements:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Anti-inflammatory”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Taxane a chemical substance derived from a yew tree of the Pacific Coast: used yew tree experimentally as a drug in the treatment of cancer. It is derived from Yew trees – Taxus Brevafolia – and bushes and used to kill dividing cells, especially tumor cells.”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “The taxanes are mitotic inhibitors, meaning that they inhibit tumors primarily by preventing cells from entering mitosis, a process of cell division. The taxanes accomplish this by inhibiting microtubule polymerization. In addition, taxanes appear to stimulate apoptosis, or programmed cell death, which is often inhibited in cancer cells.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>A video titled “Gingko Biloba Benefits” [an ingredient in Dr. Bob’s Naturals Gingko Magic] \u003C\u002Fstrong>at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=6SstxpuWwZg, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “It’s used for Alzheimer’s, memory loss ….Good for…ADHD ….It also helps with…arthritis….It also helps with…asthma…it is opening up those bronchial tubes and increasing circulation to the lungs….gingko biloba world’s most famous herb use for all your…fibromyalgia…increasing that circulation to relieve that pain…be good for MS [multiple sclerosis] as well for that reason….”\u003Cbr>\n&nbsp; o During the video, the following written statements appear as on-screen text:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Reduces Risk for Dementia\u002FAlzheimer’s”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Helps fight Fibromyalgia”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Helps fight Headaches\u002FMigraines”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your description of the video says, “Buy Our Ginkgo Veggie Capsules Here” and hyperlinks to your website https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fherbal-extracts\u002Fbrainhealth\u002Fgingko-biloba\u002Fginkgo-veggiecaps.html, and also contains the following written statements:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Helps fight Headaches\u002FMigraines”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Reduces Memory Loss”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Helps fight Muscle and Nerve Pain”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>A video titled “Increase your Synaptic Activity with Magnesium for the Brain” [an\u003Cbr>\ningredient in Dr. Bob’s Naturals Magtein]\u003C\u002Fstrong> at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=AoZv9ESLFpY, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “[m]agnesium…a lot of people have heart attacks just because they are short on magnesium….there’s another type of magnesium that gets to your brain….they started autopsying Alzheimer’s patients after they passed away and stupid monkeys and smart monkeys and they found the people with the Alzheimer’s and stupid monkeys had absolutely no magnesium in the brain and smart monkeys were full of magnesium in the brain. Well what does that tell you? Magnesium is really needed in the brain it increases synaptic activity and actually increases synapses themselves in the brain.”\u003Cbr>\n&nbsp; o During the video, the following written statement appears as on-screen text:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “6 grams (2 tsp or 12 capsules) per day if you have memory issues or DEMENTIA”.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your description of the video hyperlinks to the Dr. Bob Naturals Magtein product page of your website, https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fsupplements\u002Fmagtein\u002Fmagtein-miracle-magnesium-for-the-brain-veggie-capsules.html, and contains the following written statements:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Magnesium repairs the damaged synapses of the brain.”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Decreases the Onset Of Memory Loss”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Repairs Damaged Synapses”\u003C\u002Fp>\n\n\u003Cp>From your product labels:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Ginkgo Magic:\u003C\u002Fstrong> “Ginkgo is an anti-inflammatory”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Yew VeggieCaps:\u003C\u002Fstrong> “The Yew tree (taxus brevifolia) contains a substance called taxane. Taxanes . . . prevent harmful cells from entering mitosis. Taxane has been used in chemotherapy for many years.”\u003Cbr>\n&nbsp; &nbsp; o “Anti-Inflammatory”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Parasite Killer: \u003C\u002Fstrong>“Dr. Bob’s Parasite Killer is formulated with parasiticidal, anti-fungal, anti-viral and anti-bacterial ingredients with the intention of killing everything in the digestive tract.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Spirulina:\u003C\u002Fstrong> “Helps Balance Blood Sugar”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Chlorella:\u003C\u002Fstrong> “Helps Balance Blood Sugar”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Holy Basil Extract:\u003C\u002Fstrong> “Tulsi, or Holy Basil…. regulates insulin helping balance blood sugar levels in the body. It also contains antibacterial, antifungal, and anti-inflammatory properties.”&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Milk Thistle Liver Support:\u003C\u002Fstrong> “Milk Thistle …. is also…anti-inflammatory ….”\u003Cbr>\n&nbsp; &nbsp; o “Reduces Cholesterol\u003Cbr>\n&nbsp; &nbsp; o Reduces Insulin Resistance\u003Cbr>\n&nbsp; &nbsp; o Anti-Inflammatory\u003Cbr>\n&nbsp; &nbsp; o Asthma Support”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Stone Breaker Capsules:\u003C\u002Fstrong> “Gall and Kidney Stone Removal”\u003Cbr>\n&nbsp; &nbsp; o “Stone Breaker (Chanca Piedra) has been used…to treat and remove kidney and gall stones. It helps dissolve the stones …. Chanca Piedra interferes with stone formation by relaxing urinary passages so small stones are more easily passed.”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Dr. Bob’s Naturals Yew VeggieCaps, Gingko Magic, Milk Thistle Liver Support, Stone Breaker Capsules and Powder, and Magtein products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Dr. Bob’s Naturals Yew VeggieCaps, Gingko Magic, Milk Thistle Liver Support, Stone Breaker Capsules and Powder, and Magtein products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspection revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR 111). Based on these violations, your Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and Raw Food World Sleep Deep Powder products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they were prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>The violations include the following:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish specifications required under 21 CFR 111.70. Specifically:\u003Cbr>\na. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). For example, Chanca Piedra is an ingredient in your Dr. Bob’s Naturals Parasite Killer, but you did not establish such component specifications for Chanca Piedra. Likewise, Yuan Zhi is an ingredient in your Raw Food World Sleep Deep powder, but you did not establish such component specifications for Yuan Zhi.\u003Cbr>\nb. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or lead to the adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). For example, you did not establish any finished product specifications for Dr. Bob’s Naturals NootriTonic ULTRA, Raw Food World Sleep Deep Powder, and Dr. Bob’s Naturals Parasite Killer.\u003C\u002Fp>\n\n\u003Cp>Once you have established specifications required under 21 CFR 111.70, you must determine whether the specifications are met, as required by 21 CFR 111.75. You must also ensure that the tests and examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records of the specifications established, as required by 21 CFR 111.95(b)(1).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses, dated August 12 and August 23, 2022, in which you state you will establish specifications for the purity, strength, and composition of each of the ingredients used in your supplements, and that you will develop procedures to demonstrate that the products you manufacture meet your specifications. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of your specifications. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you have established component and finished product specifications.\u003C\u002Fp>\n\n\u003Cp>2. You must prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a), and the MMR must include the information required under 21 CFR 111.210. The MMRs used in the manufacture of your Dr. Bob’s Naturals NootriTonic ULTRA, Raw Food World Sleep Deep Powder, and Dr. Bob’s Naturals Parasite Killer, failed to include the following information, as required by 21 CFR 111.210:\u003Cbr>\na. The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label [21 CFR 111.210(d)].\u003Cbr>\nb. A statement of theoretical yield of a manufactured dietary supplement at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)].\u003Cbr>\nc. A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)].\u003Cbr>\nd. Written instructions, including specifications for each step, point or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(1)].\u003Cbr>\ne. Procedures for sampling and a cross-reference to procedures for tests or examinations [21 CFR 111.210(h)(2)].\u003Cbr>\nf. Written instructions, including specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(3)].\u003Cbr>\ng. Corrective action plans for use when a specification is not met [21 CFR 111.210(h)(5)].\u003C\u002Fp>\n\n\u003Cp>In addition, the MMRs for Dr. Bob’s Naturals Parasite Killer and Raw Food World Sleep Deep Powder also do not include the strength, concentration, weight, or measure of each dietary ingredient for each batch size [21 CFR 111.210(a)] and an accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)], nor does the MMR for Dr. Bob’s Naturals Parasite Killer include a complete list of components to be used [21 CFR 111.210(b)].\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated August 12, 2022, and August 23, 2022, in which you state you will develop written instructions and include them with your MMRs to reflect your procedures in greater detail, including quality control points, manufacturing stages, reserve collection and storage. You also state that you will implement in writing detailed manufacturing procedures, including which utensils are used, and how they should be cleaned and properly stored. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of revised MMRs for your products. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you revised your MMRs and that they are compliant with 21 CFR 111.210.\u003C\u002Fp>\n\n\u003Cp>3. You must prepare a batch production record (BPR) every time you manufactured a batch of dietary supplement, as required by 21 CFR 111.255(a), and the BPR must include the information required under 21 CFR 111.260. The BPRs you provided for your Raw Food World Sleep Deep (Lots 8070, 8079), Dr. Bob’s Naturals Parasite Killer (Lots 7036, 7087), and Dr. Bob’s Naturals NootriTonic ULTRA (Lots 8067, 8044) dietary supplements lacked the following information that must be included in a BPR, as required by 21 CFR 111.260:\u003C\u002Fp>\n\n\u003Cp>a. The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)].\u003Cbr>\nb. The date and time of maintenance, cleaning and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)].\u003Cbr>\nc. The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)].\u003Cbr>\nd. The identity and weight or measure of each component used [21 CFR 111.260(e)].\u003Cbr>\ne. A statement of the actual yield or statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)].\u003Cbr>\nf. The actual results obtained during any monitoring operations [21 CFR 111.260(g)].\u003Cbr>\ng. The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)].\u003Cbr>\nh. Documentation that the finished dietary supplement meets specifications established in accordance with 21 CFR 111.70(e) and (g) [21 CFR 111.260(i)].\u003Cbr>\ni. Documentation, at the time of performance, of the manufacture of the batch, including the information required under 21 CFR 111.260(j) [21 CFR 111.260(j)].\u003Cbr>\nj. Documentation, at the time of performance, of packaging and labeling operations, including the information required under 21 CFR 111.260(k) [21 CFR 111.260(k)].\u003Cbr>\nk. Documentation at the time of performance, that quality control personnel reviewed the batch production record, and approved and released, or rejected, the batch for distribution [21 CFR 111.260(l)(3)].\u003Cbr>\nl. Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)].\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses, dated August 12 and August 23, 2022, in which you state you will keep detailed cleaning and sanitation records for each production run of any supplement you are manufacturing, that cleaning procedures in sanitation records will become part of all your SOPs, and that each batch record will reflect what cleaning and sanitation was done before and after the batch was manufactured. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of BPRs for your products. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you have revised your BPRs and that they are compliant with 21 CFR 111.260.\u003C\u002Fp>\n\n\u003Cp>4. You failed to maintain your physical plant in a clean and sanitary condition, as required by 21 CFR 111.15(b)(1). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. In your repacking room, there was green residue built up on a ceiling vent for the A\u002FC unit, on the protective grating on a ceiling vent, and on various ceiling tiles. Further, your “Weekly Cleaning Procedure” includes wiping down walls and vents but does not include instructions for cleaning the ceiling tiles.\u003Cbr>\nb. In your new packing room, there were several multicolored stains on the walls of the room that were in direct contact with the table used for manufacturing powdered and capsuled dietary supplements. There was dark brown residue built up on a ceiling vent for the A\u002FC unit. You stated during the inspection that this room is used to repack and manufacture dietary supplements such as Dr. Bob’s Naturals Parasite Killer and to repack food products such as your Empress Blend mix, which contains raw pistachios. You provided two cleaning procedures for this room during the inspection, neither of which contains instructions for preventing allergen cross-contact, nor were you able to provide evidence of implementation of either of these procedures.\u003Cbr>\nc. In the warehouse our investigator observed a lawn mower, a snow blower, three orange gas containers, four bags of weed killer (one of which was opened), two canisters of pest control spray, two containers of engine\u002Fmotor oil, and assorted lawn and gardening equipment that were directly touching or immediately surrounding a number of your products.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses and acknowledge that in your August 23, 2022, response you indicated that the green and brown residues are caused when you do not change filters often enough, and that you will change the filters in the rooftop\u002Fheating and cooling unit.\u003C\u002Fp>\n\n\u003Cp>In addition, you stated that you cleaned the wall that had the stain on it. You also stated that all gasoline, oil, and other petroleum products have been removed from the building entirely and that you have hired a contractor to maintain the outside of the facility. However, you did not provide evidence of corrective actions, such as photographs of replaced filters, cleaned ceiling tiles and vents, and the warehouse. Further, your response did not indicate that you would update your cleaning and\u002For maintenance procedures to include cleaning ceiling tiles and a filter replacement schedule, nor did you provide a copy of updated cleaning and\u002For maintenance procedures. Therefore, we are unable to evaluate the adequacy of your corrective action.\u003C\u002Fp>\n\n\u003Cp>5. Your quality control personnel did not approve or reject written procedures that may affect the identity, purity, strength, or composition of a dietary supplement, as required by 21 CFR 111.105(a). Specifically, during the inspection, we reviewed your “Production Quality Control SOP,” “Incoming Quality Control (IQC) SOP,” “Finished Batches Meeting Product Specifications SOP,” and none of these procedures included a signature from your quality control personnel. Likewise, your quality control personnel did not approve all MMRs, as required by 21 CFR 111.123(a)(1). Specifically during the inspection, we reviewed the MMRs for Dr. Bob’s Naturals NootriTonic ULTRA (50g), Raw Food World Sleep Deep Powder (2 oz.), and Dr. Bob’s Naturals Parasite Killer (60 capsules), and none of these MMRs included a signature from your quality control personnel.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated August 12, 2022, and August 23, 2022, in which you state you will implement a more detailed quality control protocol and that you are working with a consultant to make the necessary corrections in your current system. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that your quality control unit is reviewing and approving your written procedures and master manufacturing records.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Even if your Dr. Bob’s Naturals Ginkgo Magic, Yew VeggieCaps, and Parasite Killer products were not unapproved new drugs, the products would be misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Additionally, your Dr. Bob’s Naturals NootriTonic ULTRA and The Raw Food World Sleep Deep Powder products also do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are each misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343(e)(1)] in that the labels fail to list the name and place of business of the manufacturer, packer, or distributor, in accordance with 21 CFR 101.5.\u003C\u002Fp>\n\n\u003Cp>2. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. § 343(s)(2)(B)] because they do not include a statement of identity as a “dietary supplement,” as required by 21 CFR 101.3(g).\u003C\u002Fp>\n\n\u003Cp>3. Your Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals Parasite Killer, Dr. Bob’s Naturals NootriTonic ULTRA, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product labels fail to declare all common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. The Dr. Bob’s Naturals Yew VeggieCaps and Dr. Bob’s Naturals Parasite Killer products are manufactured into capsules, but the label fails to declare the ingredients that form the capsule itself.\u003Cbr>\nb. The Dr. Bob’s Naturals Yew VeggieCaps product label fails to declare the standardized common name of Pacific Yew for the declared dietary ingredient \u003Cem>Taxus brevifolia\u003C\u002Fem> (“Yew powder”), as listed in the reference Herbs of Commerce.\u003Cbr>\nc. The Raw Food World Sleep Deep Powder product label fails to declare the standardized common name of polygala for the declared dietary ingredient \u003Cem>Yuan zhi\u003C\u002Fem>. Additionally, the product label fails to declare the standardized common name of oriental arborvitae for the declared dietary ingredient bai zi ren (\u003Cem>Platycladus orientalis\u003C\u002Fem>).\u003Cbr>\nd. The Dr. Bob’s Naturals NootriTonic ULTRA product label fails to declare the common or usual name for alpha-GPC, fruit punch flavor, and P5P.\u003Cbr>\ne. The Dr. Bob’s Parasite Killer fails to declare the standardized common name for the ingredients “Mimosa Pudica” and “Chandra Piedra” as listed in Herbs of Commerce. Mimosa Pudica is not a standardized common name, but an other common name. In addition, we note that your website indicates that “Chandra Piedra’ is an unidentified species of \u003Cem>Phyllanthus\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>4. The Raw Food World Sleep Deep Powder product is misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the product label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761) may receive a report of a serious adverse event with such dietary supplement.\u003C\u002Fp>\n\n\u003Cp>5. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the labels fail to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the products are derived, as required by 21 CFR 101.4(h)(1). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. The Dr. Bob’s Naturals Ginkgo Magic product label fails to include the part of the plant from which the Ginkgo biloba extract is derived.\u003Cbr>\nb. The Dr. Bob’s Naturals Yew VeggieCaps product label fails to include the part of the plant from which the Yew powder is derived.\u003Cbr>\nc. The Dr. Bob’s Naturals Parasite Killer product label fails to include the part of the plant from which its botanical ingredients are derived, including clove powder, wormwood, guarana, bearberry, epazote, and “mimosa pudica.”\u003Cbr>\nd. The Raw Food World Sleep Deep Powder product label fails to declare in English the part of the plant from which the bai zi ren and yuan zhi are derived.\u003C\u002Fp>\n\n\u003Cp>6. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, and Dr. Bob’s Naturals Parasite Killer products are misbranded within the meaning of section 403(q)(1)(A) [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. The dosage amount listed on Dr. Bob’s Naturals Ginkgo Magic product label suggest the consumer take a “maintenance dosage” of 2-4 capsules daily or a “health challenge” dosage of 5-8 capsules daily, but the serving size listed is 2 capsules.\u003Cbr>\nb. The dosage amount listed on Dr. Bob’s Naturals Yew VeggieCaps product label suggests the consumer take a “maintenance dosage” of 2 capsules daily or a “health challenge” dosage of 5-8 capsules daily, but the serving size listed is 2 capsules.\u003Cbr>\nc. The dosage amount listed on Dr. Bob’s Naturals Parasite Killer product label indicates two to four capsules on an empty stomach. Furthermore, the serving size of 750 mg in the Supplement Facts label does not correlate with the dosage declaration.\u003C\u002Fp>\n\n\u003Cp>7. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of sections 403(q)(5)(F) and 403(q)(1)(A) of the Act [21 U.S.C. §§ 343(q)(1)(A) and (q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.36.\u003Cbr>\nSpecifically:\u003C\u002Fp>\n\n\u003Cp>a. Dr. Bob’s Naturals Ginkgo Magic:\u003Cbr>\n&nbsp; i. The product label lists its dietary ingredient, ginkgo biloba extract, outside the nutrition label of the supplement facts label. This dietary ingredient should be listed inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\u003Cbr>\n&nbsp; ii. The product label declares nutrients with quantitative amounts of zero. Any (b)(2)-dietary ingredients not present, or in amount that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\u003C\u002Fp>\n\n\u003Cp>b. Dr. Bob’s Naturals Yew VeggieCaps\u003Cbr>\n&nbsp; i. The product label lists its dietary ingredient, “yew powder”, outside the nutrition label of the supplement facts label. This dietary ingredient should be listed inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\u003Cbr>\n&nbsp; ii. The product label contains nutrients which may be declared as zero. Any (b)(2)-dietary ingredients not present, or in amount that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\u003C\u002Fp>\n\n\u003Cp>c. Dr. Bob’s Naturals NootriTonic ULTRA\u003Cbr>\n&nbsp; i. The product label lists dietary ingredients, including alpha-GPC, tyrosine, phosphatidylserine, theanine, carnitine, and P5P, outside the nutrition label of the supplement facts label. These dietary ingredients should be listed inside the supplement facts label along with each dietary ingredient’s quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\u003Cbr>\n&nbsp; ii. The product label declares dietary ingredients with quantitative amounts of zero. Any (b)(2)-dietary ingredients not present, or in amounts that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\u003Cbr>\n&nbsp; iii. The serving size for the product must be expressed in common household measures as set forth in 21 CFR 101.9(b) and must be followed by the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams).\u003Cbr>\n&nbsp; iv. The title, “Supplement Facts,” is not in bolded font nor set at full width of the nutrition label in accordance with 21 CFR 101.36(e)(1).\u003C\u002Fp>\n\n\u003Cp>d. Dr. Bob’s Naturals Parasite Killer product label lists dietary ingredients, including papaya seed, golden seal leaf, clove powder, wormwood, guarana, bearberry, epazote, pumpkin seed, grapefruit seed, “mimosa pudica,” cayenne pepper, and black walnut hull, outside the nutrition label of the supplement facts label. These dietary ingredients should be listed inside the supplement facts label along with each dietary ingredient’s quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\u003C\u002Fp>\n\n\u003Cp>e. The Raw Food World Sleep Deep Powder product label lists dietary ingredients, including “bai zi ren” and “yuan zhi,” outside the nutrition label of the supplement facts label. These dietary ingredients should be listed as the standardized common name of each dietary ingredient inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\u003C\u002Fp>\n\n\u003Cp>f. Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, and Dr. Bob’s Naturals NootriTonic ULTRA products Supplement Facts labels each declare a statement referencing a 2,000 calorie diet. This statement is only permitted when the percent of Daily Value is declared for total fat, saturated fat, total carbohydrate, dietary fiber, or protein as required by 21 CFR 101.9(c) and 21 CFR 101.36(b)(2)(iii)(D). Furthermore, for the Dr. Bob’s Naturals Yew VeggieCaps there is no provision for the statement “Not a significant source of vitamin D, calcium, iron, and …” in the Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>8. Your Dr. Bob’s Naturals NootriTonic ULTRA product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to declare the net quantity of contents on the principal display panel as required by 21 CFR 101.7. In accordance with 21 CFR 101.7(b)(1), statements of weight shall be in terms of avoirdupois pound and ounce. The net quantity of contents statement, expressed in terms of weight, must specify both metric (i.e., grams or kilograms) and U.S. Customary System (i.e., ounces or pounds), to comply with 21 CFR 101.7 and 15 U.S.C. 1453(a)(2) of the Fair Packaging and Labeling Act.\u003C\u002Fp>\n\n\u003Cp>9. The Dr. Bob’s Naturals Parasite Killer product is misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)] in that the finished product label lists black walnut in the ingredients statement while the “Contains” statement declares that no tree nut is present in the product, which is not in accordance with section 403(w) of the Act.\u003C\u002Fp>\n\n\u003Cp>Section 201(qq) of the Act, 21 U.S.C. 321(qq), defines a major food allergen as milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, and soybeans, as well as any food ingredient that contains protein derived from one of these foods, with certain exceptions, e.g., highly refined oils derived from a major food allergen. A food is misbranded if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The word “Contains,” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or is adjacent to the list of ingredients [section 403(w)(1)(A) of the Act, 21 U.S.C. § 343(w)(1)(A)]; or\u003C\u002Fli>\n\t\u003Cli>The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived, except that the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen) [section 403(w)(1)(B) of the Act, 21 U.S.C. § 343(w)(1)(B)].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>10. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals NootriTonic ULTRA, and The Raw Food World Sleep Deep Powder are each misbranded withing the meaning of section 403(r)(6) [21 U.S.C. § 343(r)(6)] in that the products make structure function claims but fail to bear the required dietary supplement disclaimer in accordance with 21 CFR 101.93(b).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>We also have the following comments:\u003C\u002Fp>\n\n\u003Cp>1. You may confirm the identity of other components (that are not dietary ingredients) by relying on a certificate of analysis from the supplier of the component that you receive provided that you:\u003Cbr>\n&nbsp; &nbsp; • First establish component specifications, as required by 21 CFR 111.70(b).\u003Cbr>\n&nbsp; &nbsp; • Meet the requirements of 21 CFR 111.75(a)(2)(ii).\u003C\u002Fp>\n\n\u003Cp>Your Dr. Bob’s Naturals NootriTonic ULTRA product label declares “stevia’ in the Ingredient list. If you are using highly purified steviol glycosides obtained from stevia leaves in your product, please note that “stevia” refers to the botanical and is not the common or usual name of these highly purified ingredients. Rather, the common or usual name for highly purified steviol glycosides depends on the ingredient composition. If the sweetener is purified to contain 95 percent or more of a single steviol glycoside, the specific name of that single steviol glycoside is the common or usual name. For example, the name “rebaudioside A” should be used for ingredients with 95% or more rebaudioside A; the name “stevioside” should be used for ingredients with 95% or more stevioside. If the sweetener is purified to contain 95 percent or more of a mixture of two or more steviol glycosides, the name “steviol glycosides” would be the common or usual name.\u003C\u002Fp>\n\n\u003Cp>2. Your Raw Food World Sleep Deep Powder product displays text in pinyin; pinyin is considered a foreign language. A product is misbranded if the product label contains information in two languages but does not repeat all the required label information (including the nutrition information) in both languages. [section 403(f) of the Act [21 U.S.C. § 343(f)] and 21 CFR 101.15(c)].\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to do so may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Lauren Crivellone, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov or at 550 W. Jackson Blvd, Chicago, IL 60661. You may reach Ms. Crivellone at 312-206-5264 or via email at Lauren.Crivellone@fda.hhs.gov if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lawrence Stringer\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Human and Animal Food\u003Cbr>\nOperations Division East 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRobert F. McCauley\n\nRecipient Title\n\nPresident\u002FOwner\n\nSpartan Enterprises Inc. dba Watershed Wellness Center\n\n16280 National Parkway\n\nLansing, MI 48906\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nWARNING LETTER\n\nFY23-HAFE6-01 CMS 642030\n\nMarch 8, 2023\n\nDear Mr. McCauley:\n\nThe U.S. Food and Drug Administration (FDA) inspected your dietary supplement manufacturing facility, located at 16280 National Parkway, Lansing MI, from June 29 through July 25, 2022. We also reviewed your websites at www.watershed.net and www.shop.watershed.net in December 2022, and your YouTube channel. Based on inspectional findings and a review of your websites, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nUnapproved New\u002FMisbranded Drugs\n\nThis is to advise you that the FDA reviewed your product labels following the inspection of your facility. In addition, FDA reviewed your website www.shop.watershed.net in December 2022, and determined you take orders there for the products Dr. Bob’s Naturals Spirulina, Dr. Bob’s Naturals Magtein, Dr. Bob’s Naturals Tulsi-Holy Basil Extract Capsules, Dr. Bob’s Naturals Milk Thistle Liver Support, Dr. Bob’s Naturals Stone Breaker Powder, Dr. Bob’s Parasite Killer, Dr. Bob’s Naturals Parasite Killer Bundle, Dr. Bob’s Naturals Parasite Killer Bundle MINI, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals Gingko Magic, and Dr. Bob’s Naturals Chlorella, and Raw Food World Ashwagandha Extract. We also reviewed your website www.watershed.net, which directs consumers to your website www.shop.watershed.net to purchase your products, and your YouTube Channel at www.youtube.com\u002Fc\u002FDrBobMcCauley, in December 2022. The claims on your product labels, websites, and your YouTube Channel establish that these products are drugs under section 201(g)(1)(B) of the Act [21 U.SC. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the claims that provide evidence that your products are intended for use as drugs include:\n\nFrom your website at www.watershed.net:\n\no Spirulina [an ingredient in Dr. Bob’s Naturals Spirulina tablets]: the following statements are included in the description: “Lowers LDL and Triglyceride Levels”, “Anti-Inflammatory Properties”, “Fights Anemia”\n\no Ashwagandha [an ingredient in the Raw Food World Ashwagandha Extract]: the following statements are included in the description: “It is commonly used to relieve…pain, skin, joint, digestive issues asn [sic] well as neurological issues.”\n\nFrom your website at www.shop.watershed.net:\n\no Dr. Bob’s Naturals Magtei: “Magnesium repairs the damaged synapses of the brain, which is the cause of the various types of neurological and brain-related diseases.”\n\no Dr. Bob’s Naturals Tulsi-Holy Basil Extract Capsules:\n\no “Regulates Insulin Levels to Help Balance Blood Sugar”\n\no “Contains Antibacterial, Antifungal Properties”\n\no “Holy Basil…regulates insulin levels…. It has Antibacterial, anti-fungal, and anti-inflammatory properties.”\n\no Dr. Bob’s Naturals Milk Thistle Liver Support:\n\no “Milk Thistle ….is…anti-inflammatory”\n\no “Benefits:\n\n􀂃 Reduces Cholesterol\n\n􀂃 Anti-allergic\n\n􀂃 Asthma Support\n\n􀂃 Reduces Insulin Resistance\n\n􀂃 Anti-inflammatory”\n\no Dr. Bob’s Naturals Stone Breaker Powder: “Stone Breaker (Chanca Piedra) has been used by the indigenous peoples of the Amazon Forests for centuries to treat and remove of [sic] kidney and gall stones. It helps dissolve the stones so they can be eliminated from the body. Chanca Piedra interferes with stone formation by relaxing urinary passages so small stones are more easily passed. It can be used in conjunction with lithotripsy, a shock wave procedure that fragments stones”\n\no Dr. Bob’s Naturals Parasite Killer Bundle: “Six Products that kill viruses, bacteria, yeast, mold, and fungus in the bloodstream and digestive tract. Silver: Kills viruses, bacteria, yeast, mold, and fungus in the bloodstream. (16 oz) Bismuth: Kills bacteria in the digestive tract. (16 oz) Papaya Seed Powder: Parasite removal. Parasite Killer BlendTM: Kills viruses, bacteria, yeast, mold, and fungus in the digestive tract. Dissolve Bioactive Silicate: Removes biofilm and nano-bacteria from the arteries and body. Proferment [sic].”\n\no Dr. Bob’s Naturals Parasite Killer Bundle MINI: “Dr. Bob’s Parasite Killer Bundle MINI is identical to Dr. Bob’s Parasite Killer Bundle except the bottles are 2 oz (NOT 16 oz). Six Products that kill viruses, bacteria, yeast, mold, and fungus in the bloodstream and digestive tract. Silver: Kills viruses, bacteria, yeast, mold, and fungus in the bloodstream. (2 oz) Bismuth: Kills bacteria in the digestive tract. (2 oz) Papaya Seed Powder: Parasite removal. Parasite Killer BlendTM: Kills viruses, bacteria, yeast, mold, and fungus in the digestive tract. Dissolve Bioactive Silicate: Removes biofilm and nano-bacteria from the arteries and body. Preferment – Probiotic.”\n\no Dr. Bob’s Naturals Parasite Killer: “Dr. Bob’s Parasite Killer is formulated with parasiticidal, anti-fungal, anti-viral, and antibacterial ingredients with the intention of killing everything in the digestive tract. Once that is accomplished then the next step is to reintroduce probiotics, the friendly bacteria that…. keep our digestive tract free of parasites and unhealthy bacteria.”\n\nFrom your YouTube Channel:\n\no A video titled “Amazing herb – Little Known: YEW Tree with Taxane” [an ingredient in Dr. Bob’s Naturals Yew VeggieCaps] at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=kudldIcMIXU, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “Very powerful anti-cancer properties…used in conjunction with chemotherapy and other cancer treatments, but not only does it have anti-cancer properties it also has a lot of other properties as well…the way that Taxane works in the body to fight cancer is it causes cell apoptosis in cancer cells. So it doesn’t allow the cancer cell to replicate…. Is also very powerful anti-inflammatory…on top of being anti-cancer…. you take two or three capsules a day as a maintenance dosage, or if you have a serious health challenge maybe you got cancer or something, you’re going to triple that dosage and do three of those three times a day ….”\n\no Your description of the video says, “Buy Yew Capsules Here” and hyperlinks to the Dr. Bob’s Naturals Yew VeggieCaps product page of your website, https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fherbal-extracts\u002Fimmune-system-builder\u002Fyew\u002Fyewcaps.html, and also contains the following written statements:\n\n􀂃 “Anti-inflammatory”\n\n􀂃 “Taxane a chemical substance derived from a yew tree of the Pacific Coast: used yew tree experimentally as a drug in the treatment of cancer. It is derived from Yew trees – Taxus Brevafolia – and bushes and used to kill dividing cells, especially tumor cells.”\n\n􀂃 “The taxanes are mitotic inhibitors, meaning that they inhibit tumors primarily by preventing cells from entering mitosis, a process of cell division. The taxanes accomplish this by inhibiting microtubule polymerization. In addition, taxanes appear to stimulate apoptosis, or programmed cell death, which is often inhibited in cancer cells.”\n\no A video titled “Gingko Biloba Benefits” [an ingredient in Dr. Bob’s Naturals Gingko Magic] at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=6SstxpuWwZg, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “It’s used for Alzheimer’s, memory loss ….Good for…ADHD ….It also helps with…arthritis….It also helps with…asthma…it is opening up those bronchial tubes and increasing circulation to the lungs….gingko biloba world’s most famous herb use for all your…fibromyalgia…increasing that circulation to relieve that pain…be good for MS [multiple sclerosis] as well for that reason….”\n\no During the video, the following written statements appear as on-screen text:\n\n􀂃 “Reduces Risk for Dementia\u002FAlzheimer’s”\n\n􀂃 “Helps fight Fibromyalgia”\n\n􀂃 “Helps fight Headaches\u002FMigraines”\n\no Your description of the video says, “Buy Our Ginkgo Veggie Capsules Here” and hyperlinks to your website https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fherbal-extracts\u002Fbrainhealth\u002Fgingko-biloba\u002Fginkgo-veggiecaps.html, and also contains the following written statements:\n\n􀂃 “Helps fight Headaches\u002FMigraines”\n\n􀂃 “Reduces Memory Loss”\n\n􀂃 “Helps fight Muscle and Nerve Pain”\n\no A video titled “Increase your Synaptic Activity with Magnesium for the Brain” [an\n\ningredient in Dr. Bob’s Naturals Magtein] at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=AoZv9ESLFpY, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “[m]agnesium…a lot of people have heart attacks just because they are short on magnesium….there’s another type of magnesium that gets to your brain….they started autopsying Alzheimer’s patients after they passed away and stupid monkeys and smart monkeys and they found the people with the Alzheimer’s and stupid monkeys had absolutely no magnesium in the brain and smart monkeys were full of magnesium in the brain. Well what does that tell you? Magnesium is really needed in the brain it increases synaptic activity and actually increases synapses themselves in the brain.”\n\no During the video, the following written statement appears as on-screen text:\n\n􀂃 “6 grams (2 tsp or 12 capsules) per day if you have memory issues or DEMENTIA”.\n\no Your description of the video hyperlinks to the Dr. Bob Naturals Magtein product page of your website, https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fsupplements\u002Fmagtein\u002Fmagtein-miracle-magnesium-for-the-brain-veggie-capsules.html, and contains the following written statements:\n\n􀂃 “Magnesium repairs the damaged synapses of the brain.”\n\n􀂃 “Decreases the Onset Of Memory Loss”\n\n􀂃 “Repairs Damaged Synapses”\n\nFrom your product labels:\n\no Dr. Bob’s Naturals Ginkgo Magic: “Ginkgo is an anti-inflammatory”\n\no Dr. Bob’s Naturals Yew VeggieCaps: “The Yew tree (taxus brevifolia) contains a substance called taxane. Taxanes . . . prevent harmful cells from entering mitosis. Taxane has been used in chemotherapy for many years.”\n\no “Anti-Inflammatory”\n\no Dr. Bob’s Naturals Parasite Killer: “Dr. Bob’s Parasite Killer is formulated with parasiticidal, anti-fungal, anti-viral and anti-bacterial ingredients with the intention of killing everything in the digestive tract.”\n\no Dr. Bob’s Naturals Spirulina: “Helps Balance Blood Sugar”\n\no Dr. Bob’s Naturals Chlorella: “Helps Balance Blood Sugar”\n\no Dr. Bob’s Holy Basil Extract: “Tulsi, or Holy Basil…. regulates insulin helping balance blood sugar levels in the body. It also contains antibacterial, antifungal, and anti-inflammatory properties.”\n\no Dr. Bob’s Naturals Milk Thistle Liver Support: “Milk Thistle …. is also…anti-inflammatory ….”\n\no “Reduces Cholesterol\n\no Reduces Insulin Resistance\n\no Anti-Inflammatory\n\no Asthma Support”\n\no Dr. Bob’s Naturals Stone Breaker Capsules: “Gall and Kidney Stone Removal”\n\no “Stone Breaker (Chanca Piedra) has been used…to treat and remove kidney and gall stones. It helps dissolve the stones …. Chanca Piedra interferes with stone formation by relaxing urinary passages so small stones are more easily passed.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Dr. Bob’s Naturals Yew VeggieCaps, Gingko Magic, Milk Thistle Liver Support, Stone Breaker Capsules and Powder, and Magtein products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Dr. Bob’s Naturals Yew VeggieCaps, Gingko Magic, Milk Thistle Liver Support, Stone Breaker Capsules and Powder, and Magtein products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nAdulterated Dietary Supplements\n\nThe inspection revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR 111). Based on these violations, your Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and Raw Food World Sleep Deep Powder products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they were prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nThe violations include the following:\n\n1. You failed to establish specifications required under 21 CFR 111.70. Specifically:\n\na. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). For example, Chanca Piedra is an ingredient in your Dr. Bob’s Naturals Parasite Killer, but you did not establish such component specifications for Chanca Piedra. Likewise, Yuan Zhi is an ingredient in your Raw Food World Sleep Deep powder, but you did not establish such component specifications for Yuan Zhi.\n\nb. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or lead to the adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). For example, you did not establish any finished product specifications for Dr. Bob’s Naturals NootriTonic ULTRA, Raw Food World Sleep Deep Powder, and Dr. Bob’s Naturals Parasite Killer.\n\nOnce you have established specifications required under 21 CFR 111.70, you must determine whether the specifications are met, as required by 21 CFR 111.75. You must also ensure that the tests and examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records of the specifications established, as required by 21 CFR 111.95(b)(1).\n\nWe have reviewed your responses, dated August 12 and August 23, 2022, in which you state you will establish specifications for the purity, strength, and composition of each of the ingredients used in your supplements, and that you will develop procedures to demonstrate that the products you manufacture meet your specifications. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of your specifications. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you have established component and finished product specifications.\n\n2. You must prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a), and the MMR must include the information required under 21 CFR 111.210. The MMRs used in the manufacture of your Dr. Bob’s Naturals NootriTonic ULTRA, Raw Food World Sleep Deep Powder, and Dr. Bob’s Naturals Parasite Killer, failed to include the following information, as required by 21 CFR 111.210:\n\na. The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label [21 CFR 111.210(d)].\n\nb. A statement of theoretical yield of a manufactured dietary supplement at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)].\n\nc. A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)].\n\nd. Written instructions, including specifications for each step, point or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(1)].\n\ne. Procedures for sampling and a cross-reference to procedures for tests or examinations [21 CFR 111.210(h)(2)].\n\nf. Written instructions, including specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(3)].\n\ng. Corrective action plans for use when a specification is not met [21 CFR 111.210(h)(5)].\n\nIn addition, the MMRs for Dr. Bob’s Naturals Parasite Killer and Raw Food World Sleep Deep Powder also do not include the strength, concentration, weight, or measure of each dietary ingredient for each batch size [21 CFR 111.210(a)] and an accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)], nor does the MMR for Dr. Bob’s Naturals Parasite Killer include a complete list of components to be used [21 CFR 111.210(b)].\n\nWe have reviewed your responses dated August 12, 2022, and August 23, 2022, in which you state you will develop written instructions and include them with your MMRs to reflect your procedures in greater detail, including quality control points, manufacturing stages, reserve collection and storage. You also state that you will implement in writing detailed manufacturing procedures, including which utensils are used, and how they should be cleaned and properly stored. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of revised MMRs for your products. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you revised your MMRs and that they are compliant with 21 CFR 111.210.\n\n3. You must prepare a batch production record (BPR) every time you manufactured a batch of dietary supplement, as required by 21 CFR 111.255(a), and the BPR must include the information required under 21 CFR 111.260. The BPRs you provided for your Raw Food World Sleep Deep (Lots 8070, 8079), Dr. Bob’s Naturals Parasite Killer (Lots 7036, 7087), and Dr. Bob’s Naturals NootriTonic ULTRA (Lots 8067, 8044) dietary supplements lacked the following information that must be included in a BPR, as required by 21 CFR 111.260:\n\na. The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)].\n\nb. The date and time of maintenance, cleaning and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)].\n\nc. The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)].\n\nd. The identity and weight or measure of each component used [21 CFR 111.260(e)].\n\ne. A statement of the actual yield or statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)].\n\nf. The actual results obtained during any monitoring operations [21 CFR 111.260(g)].\n\ng. The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)].\n\nh. Documentation that the finished dietary supplement meets specifications established in accordance with 21 CFR 111.70(e) and (g) [21 CFR 111.260(i)].\n\ni. Documentation, at the time of performance, of the manufacture of the batch, including the information required under 21 CFR 111.260(j) [21 CFR 111.260(j)].\n\nj. Documentation, at the time of performance, of packaging and labeling operations, including the information required under 21 CFR 111.260(k) [21 CFR 111.260(k)].\n\nk. Documentation at the time of performance, that quality control personnel reviewed the batch production record, and approved and released, or rejected, the batch for distribution [21 CFR 111.260(l)(3)].\n\nl. Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)].\n\nWe have reviewed your responses, dated August 12 and August 23, 2022, in which you state you will keep detailed cleaning and sanitation records for each production run of any supplement you are manufacturing, that cleaning procedures in sanitation records will become part of all your SOPs, and that each batch record will reflect what cleaning and sanitation was done before and after the batch was manufactured. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of BPRs for your products. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you have revised your BPRs and that they are compliant with 21 CFR 111.260.\n\n4. You failed to maintain your physical plant in a clean and sanitary condition, as required by 21 CFR 111.15(b)(1). Specifically:\n\na. In your repacking room, there was green residue built up on a ceiling vent for the A\u002FC unit, on the protective grating on a ceiling vent, and on various ceiling tiles. Further, your “Weekly Cleaning Procedure” includes wiping down walls and vents but does not include instructions for cleaning the ceiling tiles.\n\nb. In your new packing room, there were several multicolored stains on the walls of the room that were in direct contact with the table used for manufacturing powdered and capsuled dietary supplements. There was dark brown residue built up on a ceiling vent for the A\u002FC unit. You stated during the inspection that this room is used to repack and manufacture dietary supplements such as Dr. Bob’s Naturals Parasite Killer and to repack food products such as your Empress Blend mix, which contains raw pistachios. You provided two cleaning procedures for this room during the inspection, neither of which contains instructions for preventing allergen cross-contact, nor were you able to provide evidence of implementation of either of these procedures.\n\nc. In the warehouse our investigator observed a lawn mower, a snow blower, three orange gas containers, four bags of weed killer (one of which was opened), two canisters of pest control spray, two containers of engine\u002Fmotor oil, and assorted lawn and gardening equipment that were directly touching or immediately surrounding a number of your products.\n\nWe have reviewed your responses and acknowledge that in your August 23, 2022, response you indicated that the green and brown residues are caused when you do not change filters often enough, and that you will change the filters in the rooftop\u002Fheating and cooling unit.\n\nIn addition, you stated that you cleaned the wall that had the stain on it. You also stated that all gasoline, oil, and other petroleum products have been removed from the building entirely and that you have hired a contractor to maintain the outside of the facility. However, you did not provide evidence of corrective actions, such as photographs of replaced filters, cleaned ceiling tiles and vents, and the warehouse. Further, your response did not indicate that you would update your cleaning and\u002For maintenance procedures to include cleaning ceiling tiles and a filter replacement schedule, nor did you provide a copy of updated cleaning and\u002For maintenance procedures. Therefore, we are unable to evaluate the adequacy of your corrective action.\n\n5. Your quality control personnel did not approve or reject written procedures that may affect the identity, purity, strength, or composition of a dietary supplement, as required by 21 CFR 111.105(a). Specifically, during the inspection, we reviewed your “Production Quality Control SOP,” “Incoming Quality Control (IQC) SOP,” “Finished Batches Meeting Product Specifications SOP,” and none of these procedures included a signature from your quality control personnel. Likewise, your quality control personnel did not approve all MMRs, as required by 21 CFR 111.123(a)(1). Specifically during the inspection, we reviewed the MMRs for Dr. Bob’s Naturals NootriTonic ULTRA (50g), Raw Food World Sleep Deep Powder (2 oz.), and Dr. Bob’s Naturals Parasite Killer (60 capsules), and none of these MMRs included a signature from your quality control personnel.\n\nWe have reviewed your responses dated August 12, 2022, and August 23, 2022, in which you state you will implement a more detailed quality control protocol and that you are working with a consultant to make the necessary corrections in your current system. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that your quality control unit is reviewing and approving your written procedures and master manufacturing records.\n\nMisbranded Dietary Supplements\n\nEven if your Dr. Bob’s Naturals Ginkgo Magic, Yew VeggieCaps, and Parasite Killer products were not unapproved new drugs, the products would be misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Additionally, your Dr. Bob’s Naturals NootriTonic ULTRA and The Raw Food World Sleep Deep Powder products also do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are each misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343(e)(1)] in that the labels fail to list the name and place of business of the manufacturer, packer, or distributor, in accordance with 21 CFR 101.5.\n\n2. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. § 343(s)(2)(B)] because they do not include a statement of identity as a “dietary supplement,” as required by 21 CFR 101.3(g).\n\n3. Your Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals Parasite Killer, Dr. Bob’s Naturals NootriTonic ULTRA, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product labels fail to declare all common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically:\n\na. The Dr. Bob’s Naturals Yew VeggieCaps and Dr. Bob’s Naturals Parasite Killer products are manufactured into capsules, but the label fails to declare the ingredients that form the capsule itself.\n\nb. The Dr. Bob’s Naturals Yew VeggieCaps product label fails to declare the standardized common name of Pacific Yew for the declared dietary ingredient Taxus brevifolia (“Yew powder”), as listed in the reference Herbs of Commerce.\n\nc. The Raw Food World Sleep Deep Powder product label fails to declare the standardized common name of polygala for the declared dietary ingredient Yuan zhi. Additionally, the product label fails to declare the standardized common name of oriental arborvitae for the declared dietary ingredient bai zi ren (Platycladus orientalis).\n\nd. The Dr. Bob’s Naturals NootriTonic ULTRA product label fails to declare the common or usual name for alpha-GPC, fruit punch flavor, and P5P.\n\ne. The Dr. Bob’s Parasite Killer fails to declare the standardized common name for the ingredients “Mimosa Pudica” and “Chandra Piedra” as listed in Herbs of Commerce. Mimosa Pudica is not a standardized common name, but an other common name. In addition, we note that your website indicates that “Chandra Piedra’ is an unidentified species of Phyllanthus.\n\n4. The Raw Food World Sleep Deep Powder product is misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the product label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761) may receive a report of a serious adverse event with such dietary supplement.\n\n5. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the labels fail to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the products are derived, as required by 21 CFR 101.4(h)(1). Specifically:\n\na. The Dr. Bob’s Naturals Ginkgo Magic product label fails to include the part of the plant from which the Ginkgo biloba extract is derived.\n\nb. The Dr. Bob’s Naturals Yew VeggieCaps product label fails to include the part of the plant from which the Yew powder is derived.\n\nc. The Dr. Bob’s Naturals Parasite Killer product label fails to include the part of the plant from which its botanical ingredients are derived, including clove powder, wormwood, guarana, bearberry, epazote, and “mimosa pudica.”\n\nd. The Raw Food World Sleep Deep Powder product label fails to declare in English the part of the plant from which the bai zi ren and yuan zhi are derived.\n\n6. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, and Dr. Bob’s Naturals Parasite Killer products are misbranded within the meaning of section 403(q)(1)(A) [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Specifically:\n\na. The dosage amount listed on Dr. Bob’s Naturals Ginkgo Magic product label suggest the consumer take a “maintenance dosage” of 2-4 capsules daily or a “health challenge” dosage of 5-8 capsules daily, but the serving size listed is 2 capsules.\n\nb. The dosage amount listed on Dr. Bob’s Naturals Yew VeggieCaps product label suggests the consumer take a “maintenance dosage” of 2 capsules daily or a “health challenge” dosage of 5-8 capsules daily, but the serving size listed is 2 capsules.\n\nc. The dosage amount listed on Dr. Bob’s Naturals Parasite Killer product label indicates two to four capsules on an empty stomach. Furthermore, the serving size of 750 mg in the Supplement Facts label does not correlate with the dosage declaration.\n\n7. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of sections 403(q)(5)(F) and 403(q)(1)(A) of the Act [21 U.S.C. §§ 343(q)(1)(A) and (q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.36.\n\nSpecifically:\n\na. Dr. Bob’s Naturals Ginkgo Magic:\n\ni. The product label lists its dietary ingredient, ginkgo biloba extract, outside the nutrition label of the supplement facts label. This dietary ingredient should be listed inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\n\nii. The product label declares nutrients with quantitative amounts of zero. Any (b)(2)-dietary ingredients not present, or in amount that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\n\nb. Dr. Bob’s Naturals Yew VeggieCaps\n\ni. The product label lists its dietary ingredient, “yew powder”, outside the nutrition label of the supplement facts label. This dietary ingredient should be listed inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\n\nii. The product label contains nutrients which may be declared as zero. Any (b)(2)-dietary ingredients not present, or in amount that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\n\nc. Dr. Bob’s Naturals NootriTonic ULTRA\n\ni. The product label lists dietary ingredients, including alpha-GPC, tyrosine, phosphatidylserine, theanine, carnitine, and P5P, outside the nutrition label of the supplement facts label. These dietary ingredients should be listed inside the supplement facts label along with each dietary ingredient’s quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\n\nii. The product label declares dietary ingredients with quantitative amounts of zero. Any (b)(2)-dietary ingredients not present, or in amounts that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\n\niii. The serving size for the product must be expressed in common household measures as set forth in 21 CFR 101.9(b) and must be followed by the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams).\n\niv. The title, “Supplement Facts,” is not in bolded font nor set at full width of the nutrition label in accordance with 21 CFR 101.36(e)(1).\n\nd. Dr. Bob’s Naturals Parasite Killer product label lists dietary ingredients, including papaya seed, golden seal leaf, clove powder, wormwood, guarana, bearberry, epazote, pumpkin seed, grapefruit seed, “mimosa pudica,” cayenne pepper, and black walnut hull, outside the nutrition label of the supplement facts label. These dietary ingredients should be listed inside the supplement facts label along with each dietary ingredient’s quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\n\ne. The Raw Food World Sleep Deep Powder product label lists dietary ingredients, including “bai zi ren” and “yuan zhi,” outside the nutrition label of the supplement facts label. These dietary ingredients should be listed as the standardized common name of each dietary ingredient inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\n\nf. Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, and Dr. Bob’s Naturals NootriTonic ULTRA products Supplement Facts labels each declare a statement referencing a 2,000 calorie diet. This statement is only permitted when the percent of Daily Value is declared for total fat, saturated fat, total carbohydrate, dietary fiber, or protein as required by 21 CFR 101.9(c) and 21 CFR 101.36(b)(2)(iii)(D). Furthermore, for the Dr. Bob’s Naturals Yew VeggieCaps there is no provision for the statement “Not a significant source of vitamin D, calcium, iron, and …” in the Supplement Facts label.\n\n8. Your Dr. Bob’s Naturals NootriTonic ULTRA product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to declare the net quantity of contents on the principal display panel as required by 21 CFR 101.7. In accordance with 21 CFR 101.7(b)(1), statements of weight shall be in terms of avoirdupois pound and ounce. The net quantity of contents statement, expressed in terms of weight, must specify both metric (i.e., grams or kilograms) and U.S. Customary System (i.e., ounces or pounds), to comply with 21 CFR 101.7 and 15 U.S.C. 1453(a)(2) of the Fair Packaging and Labeling Act.\n\n9. The Dr. Bob’s Naturals Parasite Killer product is misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)] in that the finished product label lists black walnut in the ingredients statement while the “Contains” statement declares that no tree nut is present in the product, which is not in accordance with section 403(w) of the Act.\n\nSection 201(qq) of the Act, 21 U.S.C. 321(qq), defines a major food allergen as milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, and soybeans, as well as any food ingredient that contains protein derived from one of these foods, with certain exceptions, e.g., highly refined oils derived from a major food allergen. A food is misbranded if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\n\nThe word “Contains,” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or is adjacent to the list of ingredients [section 403(w)(1)(A) of the Act, 21 U.S.C. § 343(w)(1)(A)]; or\n\nThe common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived, except that the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen) [section 403(w)(1)(B) of the Act, 21 U.S.C. § 343(w)(1)(B)].\n\n10. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals NootriTonic ULTRA, and The Raw Food World Sleep Deep Powder are each misbranded withing the meaning of section 403(r)(6) [21 U.S.C. § 343(r)(6)] in that the products make structure function claims but fail to bear the required dietary supplement disclaimer in accordance with 21 CFR 101.93(b).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nWe also have the following comments:\n\n1. You may confirm the identity of other components (that are not dietary ingredients) by relying on a certificate of analysis from the supplier of the component that you receive provided that you:\n\n• First establish component specifications, as required by 21 CFR 111.70(b).\n\n• Meet the requirements of 21 CFR 111.75(a)(2)(ii).\n\nYour Dr. Bob’s Naturals NootriTonic ULTRA product label declares “stevia’ in the Ingredient list. If you are using highly purified steviol glycosides obtained from stevia leaves in your product, please note that “stevia” refers to the botanical and is not the common or usual name of these highly purified ingredients. Rather, the common or usual name for highly purified steviol glycosides depends on the ingredient composition. If the sweetener is purified to contain 95 percent or more of a single steviol glycoside, the specific name of that single steviol glycoside is the common or usual name. For example, the name “rebaudioside A” should be used for ingredients with 95% or more rebaudioside A; the name “stevioside” should be used for ingredients with 95% or more stevioside. If the sweetener is purified to contain 95 percent or more of a mixture of two or more steviol glycosides, the name “steviol glycosides” would be the common or usual name.\n\n2. Your Raw Food World Sleep Deep Powder product displays text in pinyin; pinyin is considered a foreign language. A product is misbranded if the product label contains information in two languages but does not repeat all the required label information (including the nutrition information) in both languages. [section 403(f) of the Act [21 U.S.C. § 343(f)] and 21 CFR 101.15(c)].\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to do so may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Lauren Crivellone, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov or at 550 W. Jackson Blvd, Chicago, IL 60661. You may reach Ms. Crivellone at 312-206-5264 or via email at Lauren.Crivellone@fda.hhs.gov if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nLawrence Stringer\n\nActing Program Division Director\n\nOffice of Human and Animal Food\n\nOperations Division East 6","Spartan Enterprises Inc. dba Watershed Wellness Center","spartan-enterprises-inc-dba-watershed-wellness-center-642030-03082023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspartan-enterprises-inc-dba-watershed-wellness-center-642030-03082023","2026-10-26T08:10:02.613344+00:00","2023-04-25","642030","DrugsFood & Beverages","Division of Human and Animal Food Operations East VI","Robert F. McCauley","2026-08-20T01:08:53.457+00:00","2023-03-08",4,{"510k":99,"classification":100,"enforcement":101,"event":102,"event_backfill":103,"pma":104,"warning_letter":105},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]